Megan Kruse, MD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) (NCT06214793) | Megan Kruse, MD | 2026-10-01 |
Track Megan Kruse, MD automatically
Every clearance here is in the API, with alerts when new ones post.